Trial reportAlimentary pharmacology & therapeutics2021
Randomised study: effects of the 5-HT
Trial report in Alimentary pharmacology & therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03281577 (A Dose-Ranging, Randomized, Parallel, Placebo-Controlled Study to Assess the Effect of TAK-954 on Gastrointestinal and Colonic Transit in Patients With Diabetic or Idiopathic Gastroparesis), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Dose-Ranging, Randomized, Parallel, Placebo-Controlled Study to Assess the Effect of TAK-954 on Gastrointestinal and Colonic Transit in Patients With Diabetic or Idiopathic Gastroparesis
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- Trial
- The Effect of Hepatic Impairment on the Pharmacokinetics of Intravenously Administered Felcisetrag (TAK-954).Journal of clinical pharmacology · 2022Trial
- Randomised study: effects of the 5-HTAlimentary pharmacology & therapeutics · 2021Trial
- Prokinetic drugs that stimulate 5-HTNaunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Progress in Gastroparesis Management: From Pharmacotherapy to Interventional Treatments.JGH open : an open access journal of gastroenterology and hepatology · 2026Review
- Felcisetrag stimulates 5-HTNaunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Pharmacologic treatments for gastroparesis.Pharmacological reviews · 2025Review
- Long-term tuina can inhibit the occurrence of gastroparesis by protecting gastrointestinal function in diabetic rats.Frontiers in endocrinology · 2025Article
- Mechanism of action of FoxiangSan in diabetic gastroparesis: Gut microbiota and cAMP/PKA pathway.Heliyon · 2024Article
- Common Pathophysiological Mechanisms and Treatment of Diabetic Gastroparesis.Journal of neurogastroenterology and motility · 2024Review
- The Use of Pre-Endoscopic Metoclopramide Does Not Prevent the Need for Repeat Endoscopy: A U.S. Based Retrospective Cohort Study.Life (Basel, Switzerland) · 2024Article
- Review
- Gastric schwannoma with post-surgical gastroparesis: a case report and literature review.Frontiers in oncology · 2024Article
- Imaging in Gastroparesis: Exploring Innovative Diagnostic Approaches, Symptoms, and Treatment.Life (Basel, Switzerland) · 2023Review
- Reconsideration of the Gastroparetic Syndrome.Current gastroenterology reports · 2023Review
- Enterochromaffin Cells-Gut Microbiota Crosstalk: Underpinning the Symptoms, Pathogenesis, and Pharmacotherapy in Disorders of Gut-Brain Interaction.Journal of neurogastroenterology and motility · 2022Review
- Current Treatment Options and Therapeutic Insights for Gastrointestinal Dysmotility and Functional Gastrointestinal Disorders.Frontiers in pharmacology · 2022Review
- Gastroparesis.Gastroenterology · 2022Review
- New Developments in Prokinetic Therapy for Gastric Motility Disorders.Frontiers in pharmacology · 2021Review
Corrections and comments
- Commented on by
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundGastroparesis is defined by delayed gastric emptying with associated symptoms in the absence of mechanical obstruction.
aimTo evaluate pharmacokinetics and pharmacodynamics of felcisetrag, a highly selective 5-HT
methodsSingle-centre, placebo-controlled study of 36 participants receiving placebo, 0.1mg, 0.3mg or 1.0mg of felcisetrag I.V. infusion, daily, for 3 days. At baseline, each participant completed a 4h,
resultsPatients (22 idiopathic, 14 diabetic gastroparesis) were randomised to felcisetrag (0.1 mg, n = 10; 0.3 mg, n = 9; 1.0 mg, n = 7) or placebo (n = 10). Compared to placebo, felcisetrag significantly accelerated gastric emptying T
conclusionI.V. felcisetrag significantly accelerated gastric, small bowel and colonic transit in patients with gastroparesis, and should be further evaluated for short-term treatment of gastric and intestinal motility disorders. ClinicalTrials.gov #NCT03281577.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.